Oncology PracticeICYMI: Elotuzumab reduces progression risk in lenalidomide-refractory multiple myelomaNovember 7, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsFDA approves elotuzumab with pom/dex in refractory myelomaNovember 7, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesCombo appears safe, active in rel/ref NHLNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology TimesSandoz won’t seek U.S. approval for rituximab biosimilarNovember 6, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular LymphomaB Cell Lymphoma
Hematology NewsSandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018CLLLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular LymphomaB Cell Lymphoma
Hematology TimesFDA and EC approve pegfilgrastim biosimilarNovember 4, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacy
Hematology NewsHaploidentical transplantation holds promise in relapsed myelomaNovember 3, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesHealth Canada approves pralatrexate for rel/ref PTCLNovember 2, 2018Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesEC approves venetoclax in combo with rituximabNovember 2, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsGenomic abnormalities shed light on racial disparity in myelomaNovember 1, 2018Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesNovel risk factors for febrile neutropenia in NHL, other cancersNovember 1, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesPalliative care guidelines relevant for hematologists, doc saysNovember 1, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingPediatricsRelated Issues
Hematology NewsCheckpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular LymphomaB Cell Lymphoma
The Journal of Community and Supportive OncologyVenetoclax approved to treat CLL patients regardless of genotypeOctober 28, 2018Lymphoma & Plasma Cell Disorders
Hematology NewsLine complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Aggressive LymphomasThrombosisLymphoma & Plasma Cell DisordersB Cell Lymphoma
